Here's Why Unity Biotechnology Is Getting Crushed Today
The development-stage biopharma announced disappointing results from a clinical trial.
Unity Biotechnology, Inc.
Symbol | Last Price | Market Cap | % Δ 1 Yr | % Δ 5 Yr |
---|---|---|---|---|
UBX
Unity Biotechnology, Inc.
|
$0.85 | $59M | -80.6% | |
CWBHF |
$0.49 | $72M | -85.3% | |
CNTTQ |
$0.05 | $7M | -91.8% | |
XLY |
$0.14 | $138M | -51.6% | -88.7% |
PANC.DL |
$0.00 | $53 | -99.9% | -99.9% |
The development-stage biopharma announced disappointing results from a clinical trial.
Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?
The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.